Entyvio Alternatives Compared
Entyvio | Vedolizumab | Upadacitinib |
|
---|
Entyvio (vedolizumab) | Vedolizumab | Upadacitinib |
|
|||||||
---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Entyvio infusion is an integrin receptor antagonist that may be used to reduce inflammation associated with moderate to severe ulcerative colitis or Crohn's disease. It targets the gut specifically... View more |
Prescription only
Prescribed for Ulcerative Colitis, Crohn's Disease - Maintenance, Crohn's Disease. vedolizumab may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Ankylosing Spondylitis, Crohn's Disease, Atopic Dermatitis, Non-Radiographic Axial Spondyloarthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Rheumatoid... View more |
Related suggestions Ulcerative Colitis
Crohn's Disease
|
|||||||
More about Entyvio (vedolizumab) | More about Vedolizumab | More about Upadacitinib | ||||||||
Ratings & Reviews | ||||||||||
Entyvio has an average rating of 6.1 out of 10 from a total of 152 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 29% reported a negative effect. |
Vedolizumab has an average rating of 6.1 out of 10 from a total of 172 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 29% reported a negative effect. |
Upadacitinib has an average rating of 6.8 out of 10 from a total of 178 ratings on Drugs.com. 54% of reviewers reported a positive effect, while 23% reported a negative effect. |
||||||||
Drug Class | ||||||||||
Side Effects | ||||||||||
See also: Entyvio side effects in more detail. |
See also: vedolizumab side effects in more detail. |
See also: upadacitinib side effects in more detail. |
||||||||
Generic Availability | ||||||||||
N/A |
N/A |
N/A |
||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||
View all Entyvio prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
Dosage Form(s) Available | ||||||||||
|
N/A |
N/A |
||||||||
Brand Names | ||||||||||
Other vedolizumab brands include: Entyvio Pen | Entyvio, Entyvio Pen | Rinvoq, Rinvoq LQ | ||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
600 hours |
600 hours |
14 hours |
||||||||
CSA Schedule ** View glossary of terms | ||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
Pregnancy Category | ||||||||||
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
Drug Interactions | ||||||||||
A total of 152 drugs are known to interact with Entyvio:
|
A total of 152 drugs are known to interact with vedolizumab:
|
A total of 551 drugs are known to interact with upadacitinib:
|
||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||
Disease Interactions | ||||||||||
First Approval Date | ||||||||||
May 20, 2014 |
May 20, 2014 |
August 16, 2019 |
||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||
N/A |
N/A |
N/A |
||||||||
More Information | ||||||||||
Patient resources | ||||||||||
Professional Resources | ||||||||||
Related Treatment Guide | ||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.